简体中文
English
Kogan Y, Elishmereni M, Taub E, Agur Z. Increase in tumor burden at disease progression as a predictor of survival in advanced NSCLC patients. J Clin Oncol 36, 2018 (suppl; abstr e21114).
Kogan Y, Kleiman M, Shannon S, Elishmereni E, Taub E, Aptekar L, Brenner R. M, Berger R, Nechushtan H, Agur Z. A new algorithm predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of five serum biomarkers. J Clin Oncol 36, 2018 (suppl; abstr e21190).
Y. Kogan, M. Kleiman, S. Shannon, M. Elishmereni, E. Taub, L. Aptekar, R. Brenner, R. Berger, H. Nechushtan, Z. Agur. 176P PrediCare: A new diagnostic tool predicting imminent disease progression in advanced NSCLC patients by machine-learning integration of three serum biomarkers. Journal of Thoracic Oncology , Volume 13 , Issue 4 , S105.
Elishmereni M, Kheifetz Y, Shukrun I, Bevan GH, Nandy D, McKenzie KM, Kohli M, Agur Z. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. Prostate. 2016;76(1):48-57. doi: 10.1002/pros.23099. PubMed PMID: 26419619.
Kheifetz, Y., Elishmereni, M., Agur, Z. Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein. J Pharmacokinet Pharmacodyn 2014 41(5) pp. 479-491., PMID: 25231819.
Agur Z, Elishmereni M, Kheifetz Y. Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration. Wiley Interdiscip Rev Syst Biol Med. 2014;6(3):239-53. doi: 10.1002/wsbm.1263. PubMed PMID: 24604755.
Vainas O, Ariad S, Amir O, Mermershtain W, Vainstein V, Kleiman M, Inbar O, Ben-Av R, Mukherjee A, Chan S, Agur Z. Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model. Br J Cancer. 2012;107(5):814-22. Epub 2012/07/21. doi: bjc2012316 [pii], 10.1038/bjc.2012.316. PubMed PMID: 22814580; PMCID: 3425973.
Jager E., van der Velden V.H., Te Marvelde JG., Walter R.B., Agur Z., Vainstein V. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS one 2011 6(9) e24265.
Elishmereni M, Kheifetz Y, Søndergaard H, Viig R. O, Agur Z. An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers.PLoS Computational Biology 2011 7(9) e1002206.
Agur Z. From the Evolution of Toxin Resistance to Virtual Clinical Trials – the Role of Mathematical Models in Oncology, Future Oncology, 2010;6(6), (pp. 917-27).
Gorelik B., Ziv I., Shohat R., Wick M., Hankins D., Sidransky D., Agur Z. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008;68(21), (pp. 9033–9040).
Agur Z., Elishmereni M., Kogan Y., Kheiffetz Y., Ziv I., Shoham M., and Vainstein V. "Mathematical modeling as a new approach for improving the efficacy/toxicity profile of drugs: the thrombocytopenia case study" in 'Preclinical Development Handbook', Shayne Gad Ed., John Wiley & Sons, USA. 2008, pp 1229-1266.
Agur Z., Hassin R., Levy S. Optimizing chemotherapy scheduling using local search heuristics, Operations Research. 2006 Sep;54 (5) 2006 (pp.829-846).
Agur Z. Biomathematics in the development of personalized medicine in oncology. Future Oncol. 2006 Feb;2 (1):39-42.
Vainstein V, Ginosar Y, Shoham M, Ranmar DO, Ianovski A, Agur Z. The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. J Theor Biol. 2005;234(3):311-27. PubMed PMID: 15784267.